Nuclera

Nuclera is a biotechnology startup founded in 2013 with a mission to improve human health through accessible proteins. Their innovative eProtein Discovery™ system aims to expedite protein projects by providing rapid access to high-quality, soluble, active proteins at the benchtop. This system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours and allows protein scale-up to the mg scale in less than 48 hours. Nuclera's technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, offering a high-throughput protein access system. The company, which originated with PhD students at the University of Cambridge, now operates in Cambridge, UK and Boston, MA, employing over 100 individuals. Its most recent Series C funding round saw an investment of $75.00M on 16 October 2024 from prominent investors including Verve Ventures, Cambridge Innovation Capital, Patient Square Capital, Elevage Medical Technologies, British Business Bank, Jonathan Milner, GK Goh, M&G Catalyst, E Ink Holdings, Michael D. McCreary, Uni Power Group.